Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Imbruvica:

How I treat CLL patients with ibrutinib. Brown JR et al. Blood. (2018)

Cardiovascular Side Effects of Tyrosine Kinase Inhibitor Ibrutinib (Imbruvica) and Interaction With Direct Oral Anticoagulant. Khalid M et al. Am J Ther. (2018)

Chronic lymphocytic leukaemia. Hallek M et al. Lancet. (2018)

Search results

Items: 1 to 20 of 33

1.

Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy
.

Mosna K, Ladicka M, Drgona L, Vranovska M, Hojsikova I, Tomasova R, Danihel L Jr, Kyselovic J, Babal P.

Int J Clin Pharmacol Ther. 2020 Mar 26. doi: 10.5414/CP203663. [Epub ahead of print]

PMID:
32213285
2.

FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.

King-Kallimanis BL, Wroblewski T, Kwitkowski V, De Claro RA, Gwise T, Bhatnagar V, Farrell AT, Kluetz PG.

Qual Life Res. 2020 Feb 25. doi: 10.1007/s11136-020-02448-y. [Epub ahead of print]

PMID:
32100182
3.

In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.

[No authors listed]

Med Lett Drugs Ther. 2018 Nov 5;60(1559):e184. No abstract available.

PMID:
30681658
4.

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.

van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.

Mol Pharm. 2018 Nov 5;15(11):5124-5134. doi: 10.1021/acs.molpharmaceut.8b00702. Epub 2018 Oct 10.

PMID:
30247919
5.

Ibrutinib.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

6.

Cardiovascular Side Effects of Tyrosine Kinase Inhibitor Ibrutinib (Imbruvica) and Interaction With Direct Oral Anticoagulant.

Khalid M, Khattak F, Ramu V.

Am J Ther. 2018 Nov/Dec;25(6):e768-e769. doi: 10.1097/MJT.0000000000000775. No abstract available.

PMID:
29916856
7.

Imbruvica®▾(ibrutinib) patient support programme for chronic lymphocytic leukaemia and mantle cell lymphoma.

Murthy V, Weaving S, Paneesha S.

Br J Nurs. 2017 May 25;26(10):S20-S25. doi: 10.12968/bjon.2017.26.10.S20.

PMID:
28541116
8.

Efficient synthesis of (S)-N-Boc-3-hydroxypiperidine using an (R)-specific carbonyl reductase from Candida parapsilosis.

Chen J, Yan M, Xu L.

World J Microbiol Biotechnol. 2017 Mar;33(3):61. doi: 10.1007/s11274-016-2189-y. Epub 2017 Feb 27.

PMID:
28243985
9.

Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.

Deeks ED.

Drugs. 2017 Feb;77(2):225-236. doi: 10.1007/s40265-017-0695-3. Review.

PMID:
28105602
10.

Efficient Preparation of (S)-N-Boc-3-Hydroxylpiperidine Through Bioreduction by a Thermostable Aldo-KetoReductase.

He M, Zhou S, Cui M, Jin X, Lai D, Zhang S, Wang Z, Chen Z.

Appl Biochem Biotechnol. 2017 Apr;181(4):1304-1313. doi: 10.1007/s12010-016-2285-3. Epub 2016 Nov 16.

PMID:
27854034
11.

ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.

[No authors listed]

Prescrire Int. 2016 Oct;25(175):232.

PMID:
30645823
12.

Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia.

Raedler LA.

Am Health Drug Benefits. 2016 Mar;9(Spec Feature):89-92. No abstract available.

13.

Spontaneous Iliopsoas Muscle Hemorrhage Secondary to Ibrutinib (Imbruvica; Pharmacyclics): Brief Report.

Sarcon A, Botta GP, Patel N, Saven A.

J Investig Med High Impact Case Rep. 2016 May 9;4(2):2324709616648457. doi: 10.1177/2324709616648457. eCollection 2016 Apr-Jun.

14.
15.
16.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.

de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, Brower ME, Chang CJ, Pfuma E, Habtemariam B, Bullock J, Wang Y, Nie L, Chen XH, Lu DR, Al-Hakim A, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Aug 15;21(16):3586-90. doi: 10.1158/1078-0432.CCR-14-2225.

17.

[Ibrutinib: A new drug of B-cell malignancies].

Thieblemont C.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S85-90. doi: 10.1016/S0007-4551(15)31222-4. Review. French.

PMID:
26118882
18.

Possible influence of some foods on the metabolism of ibrutinib.

Kronabel D.

Clin Lab. 2015;61(3-4):443-4.

PMID:
25975016
19.

Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.

Kim ES, Dhillon S.

Drugs. 2015 May;75(7):769-76. doi: 10.1007/s40265-015-0380-3. Review.

PMID:
25802231
20.

Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.

Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F.

Cancer Res. 2015 Feb 1;75(3):594-604. doi: 10.1158/0008-5472.CAN-14-2362. Epub 2015 Jan 14.

Supplemental Content

Loading ...
Support Center